Oslo, Norway, November 2025 — Actithera, a pioneering radiopharmaceutical biotechnology company, has announced the appointment of Dimitrios Mantzilas as Chief Technology Officer and Site Head for Actithera Oslo. In this dual leadership role, Dimitrios will oversee global technology strategy, R&D initiatives, and operations at Actithera’s Oslo site, driving innovation in next-generation radioligand therapies (RLTs).
Before joining Actithera, Dimitrios Mantzilas served as Chief Technology Officer at Precirix, a biotechnology company dedicated to advancing precision radiopharmaceuticals for cancer treatment. Over his four-year tenure, he played a key role in the design and development of targeted radiopharmaceuticals using camelid single-domain antibodies labeled with radiometals, contributing to the company’s clinical and regulatory success.
Prior to that, Dimitrios spent more than seven years at Bayer, where he held multiple leadership roles, including Head of Radiopharmaceutical Development (CPD Oslo) and Head of Technology Development. His work at Bayer was instrumental in advancing radiopharmaceutical R&D programs, technical transfers, and regulatory compliance processes, strengthening the company’s footprint in oncology innovation.
Earlier, Dimitrios served as Director of Technology Development at Algeta ASA, where he led key development programs before the company’s acquisition by Bayer. His career also includes nearly a decade at GE Healthcare, where he held positions such as CMC Coordinator, Technology Transfer Leader, and Senior Research Scientist. During his tenure, he played an essential role in enabling PET clinical trials worldwide, leading GMP manufacturing, regulatory documentation, and analytical chemistry programs.
In addition to his corporate leadership, Dimitrios currently serves on the Board of Directors at TAG1 Inc., a medical radioisotope company focused on radioligand therapy supply, and at Extraction Technologies Norway AS, where he supports the development of groundbreaking electromembrane extraction technologies for blood compound analysis.
About Actithera
Actithera is a next-generation radiopharmaceutical biotechnology company translating medicinal chemistry insights into innovative radioligand therapies (RLTs). Founded in 2021 by Dr. Andreas Goutopoulos with backing from M Ventures and Arkin Bio Ventures II, the company leverages unique molecular design strategies—such as covalent-targeting and an isotope-agnostic approach—to develop differentiated radioligand therapies with expanded therapeutic windows.
Headquartered in Oslo, Norway, with operations in Cambridge, Massachusetts, Actithera is committed to addressing unmet needs in oncology through precision-targeted, high-efficacy RLTs that enhance patient outcomes and redefine cancer care.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
